However, should ceramide rather than C1P deficiency be the major driver of insulin resistance in our model, then the administration of C1P in diabetes would result in increased ceramide production and further worsening of DKD, and the observed improvement of AKT phosphorylation in vitro and in vivo would remain unexplained. This evidence concerns the gene AKT1 and diabetic kidney disease.